In this kick-off segment, epilepsy expert Scott Perry, MD, explains how zorevunersen uses antisense oligonucleotide technology to correct SCN1A gene expression and address the underlying cause of Dravet syndrome.
Zorevunersen and the Next Chapter of Dravet Syndrome Care
Epileptologist Scott Perry, MD, reviews findings from the early-phase Monarch and Admiral trials, highlighting zorevunersen’s dose-response profile, seizure reduction, and safety outcomes. [WATCH TIME: 3 minutes]
In this segment, epileptologist Scott Perry, MD, discusses zorevunersen’s effects on Vineland-3 scores and why improvements in communication, cognition, and adaptive behavior matter in Dravet syndrome. [WATCH TIME: 3 minutes]
In this fourth segment, Scott Perry, MD, outlines the design of the registrational EMPEROR trial and what it aims to confirm about zorevunersen’s long-term safety and clinical benefit. [WATCH TIME: 2 minutes]
In this final segment, Perry reflects on how zorevunersen represents a shift toward disease-modifying therapies in epilepsy and what this means for the future of genetic epilepsies. [WATCH TIME: 2 minutes]
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Enhancing Stroke Systems of Care
2
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
3
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
4
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
5
